Clinical trials: Antineoplastic Treatment
Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Conditions
- Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity
- Trial name
- NCT01399372
- Testing
- Rituximab, Cytarabine, Methotrexate
- Where
- 45 sites in United States, Israel
- Volunteers
- 91 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2…
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma
- Trial name
- NCT02466971
- Testing
- Brachytherapy, Cisplatin, External Beam Radiation Therapy
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
This phase II trial is studying how well giving SGN-30 together with combination chemotherapy works in treating patients with newly diagnosed anaplastic large cell lymphoma.
- Trial name
- NCT00365274
- Testing
- Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04616534
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Head and Neck Carcinoma, Recurrent or Metastatic Disease
Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
PURPOSE: Cetuximab with platinum and 5FU is now the standard combination as first-line treatment in patients with metastatic or recurrent Head and Neck squamous cell carcinomas.
- Trial name
- TPEx (NCT01289522)
- Testing
- cetuximab IV, Biopsies
- Where
- 14 sites in Belgium, France
- Volunteers
- 54 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Adult Diffuse Large Cell Lymphoma, Recurrent
DPX-Survivac and Checkpoint Inhibitor in DLBCL
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two…
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- SPiReL (NCT03349450)
- Testing
- DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
- Where
- 6 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Medication Adherence
Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence
Oral chemotherapeutic agents (OCAs) are increasingly being used as an alternative to traditional intravenous chemotherapy, and factors promoting this trend include increased survival times requiring long-term therapy…
- Trial name
- NCT02543723
- Testing
- Nurse Coach Intervention
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- East Carolina University
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759587
- Testing
- Niraparib
- Where
- 27 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Acute Lymphoblastic Leukemia, Pediatric
Vaccine Immune Recovery After Leukemia
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia…
- Trial name
- VIRAL (NCT05622682)
- Testing
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Where
- 6 sites in United States
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
Atherosclerosis, Vascular Disease
LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
The purpose of the study is to assess the safety and efficacy of the Lutonix Catheter for treatment of stenosis of the femoropopliteal arteries by direct comparison to standard balloon angioplasty.
- Conditions
- Atherosclerosis, Vascular Disease, Arteriosclerosis
- Trial name
- LEVANT I (NCT00930813)
- Testing
- Lutonix Catheter, Standard uncoated Balloon Angioplasty Catheter
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 101 people
- Sponsor
- C. R. Bard
Triple-Negative Breast Cancer
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
- Trial name
- NCT04177108
- Testing
- Atezolizumab, Ipatasertib, Paclitaxel
- Where
- 182 sites in United States, Argentina and 35 more
- Volunteers
- 242 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Basal Cell, Carcinoma, Squamous Cell
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
The main purpose of this study is to see if 5-fluorouracil (5-FU) skin cream can prevent the growth of new skin cancers on the face and ears.
- Conditions
- Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases
- Trial name
- VAKCCT (NCT00847912)
- Testing
- 5-fluorouracil
- Where
- 13 sites in United States
- Volunteers
- 954 people
- Sponsor
- VA Office of Research and Development
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Stage IV Colorectal Cancer
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced colorectal cancer who have failed at least…
- Trial name
- NCT01550510
- Testing
- Ascorbic Acid, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in treating patients with HER2 positive stage…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT04108858
- Testing
- Copanlisib, Pertuzumab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Neoplasms
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- NCT05678257
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan
- Where
- 59 sites in United States, France and 4 more
- Volunteers
- 180 people
- Sponsor
- NuCana plc
Breast Neoplasms, HER2/Neu Positive
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where…
- Conditions
- Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
- Trial name
- NCT01273610
- Testing
- Lapatinib, Trastuzumab, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational…
- Trial name
- NCT02551055
- Testing
- MLN1117, TAK-659, Alisertib
- Where
- 6 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Millennium Pharmaceuticals, Inc.